Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
1. To evaluate the effect of S-2367 on body weight when administered following a 6-week
placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet
compared to placebo in healthy obese male and female subjects
2. To evaluate the safety and tolerability of S-2367 during 54 weeks of drug exposure
3. To evaluate the steady-state/trough pharmacokinetics of S-2367